Kairos Pharma Ltd. (KAPA)
AMEX: KAPA
· Real-Time Price · USD
1.12
-0.07 (-6.28%)
At close: Sep 25, 2025, 3:59 PM
1.14
1.79%
After-hours: Sep 25, 2025, 05:02 PM EDT
-6.28% (1D)
| Bid | 1.11 |
| Market Cap | 23.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.71M |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | -4.15 |
| Forward PE | -3.11 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.16 |
| Volume | 693,176 |
| Avg. Volume (20D) | 5,200,098 |
| Open | 1.19 |
| Previous Close | 1.20 |
| Day's Range | 1.10 - 1.21 |
| 52-Week Range | 0.40 - 3.25 |
| Beta | 2.36 |
| Ex-Dividend Date | n/a |
About KAPA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KAPA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KAPA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-20.24%
Kairos Pharma shares are trading lower. The compan...
Unlock content with
Pro Subscription
2 months ago
+70.8%
Kairos Pharma shares are trading higher after the company announced safety results from its Phase 2 trial of ENV-105 in advanced prostate cancer.
